The Use of Recombinant Tissue Plasminogen Activator (rTPA) in The Treatment of Fibrinous Pleuropneumonia in Horses: 25 Cases (2007–2012)

BACKGROUND: Information about treatment protocols, adverse effects and outcomes with intrapleural recombinant tissue plasminogen activator (rTPA) use in horses with fibrinous pleuropneumonia is limited. HYPOTHESIS/OBJECTIVES: Describe factors that contribute to clinical response and survival of hors...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Vet Intern Med
Main Authors: Tomlinson, J.E., Byrne, E., Pusterla, N., Magdesian, K. Gary, Hilton, H.G., McGorum, B., Davis, E., Schoster, A., Arroyo, L., Dunkel, B., Carslake, H., Boston, R.C., Johnson, A.L.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2015
Assuntos:
EQUID
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4858032/
https://ncbi.nlm.nih.gov/pubmed/26256909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvim.13594
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados